Filing identity and business context
Important mismatch: The supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q for the quarter and nine months ended March 31, 2023, filed May 11, 2023. It is not a Tuhura Biosciences filing or a 2022 Q3 report. Figures below are in U.S. dollars, generally in thousands, except per-share data.
Kintara is a clinical-stage oncology company developing VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. The company has not generated revenue. REM-001 was paused in October 2022 to preserve cash for VAL-083 development.
Financial performance and liquidity
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 | Nine months ended March 31, 2023 | Nine months ended March 31, 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $2,005 | $3,474 | $7,235 | $11,169 |
| General and administrative expense | $1,297 | $1,884 | $4,212 | $6,055 |
| Net loss | $3,264 | $5,356 | $11,314 | $17,215 |
| Basic and diluted loss per share | $(1.94) | $(5.45) | $(7.32) | $(22.39) |
| Net cash used in operating activities | Not separately stated for the quarter | $10,357 | $15,400 |
Margins are not meaningful because the company reported no revenue. Net loss improved year over year as operating expenses declined; management attributed the reductions mainly to lower clinical-development spending, the REM-001 pause, lower personnel costs, and reduced share-based compensation and professional fees.
At March 31, 2023, cash and cash equivalents were $3,045, versus $11,780 at June 30, 2022. Working capital was $3,226; current assets were $6,016 and current liabilities were $2,790. Total assets were $6,740, total liabilities $2,954, and stockholders’ equity $3,786. The filing reports a $164 milestone payment liability and no conventional borrowings are identified in the provided financial statements.
Nine-month investing cash outflow was $232, principally for equipment. Financing provided $1,854, including $1,860 net proceeds from common-stock sales under the Lincoln Park agreement, less preferred dividends. The company ended the period with $3,045 cash. The filing does not provide a definitive cash runway estimate.
Material changes and notable items
- Nine-month net loss narrowed to $11,314 from $17,215; operating cash use fell to $10,357 from $15,400.
- Cash declined by $8,735 during the nine months. The Lincoln Park facility generated $1,860 in net proceeds, but the company said the amount then available had reached its current maximum because of Nasdaq ownership limitations.
- The company paid a Series C stock dividend valued at $362 during the nine-month period, compared with $2,462 in the prior-year period. The Series C preferred stock carries additional dividend rights; outstanding shares were convertible into approximately 245,000 common shares at March 31, 2023.
- A 1-for-50 reverse stock split took effect in November 2022. Share and per-share amounts are retrospectively adjusted in the filing.
Outlook, risks, and contingencies
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year of the filing. It needs additional funding for trials, research and development, and operations; planned options include equity, debt, or strategic partnerships, none assured.
- Clinical outlook: Kintara expected topline results from its VAL-083 GBM AGILE study around the end of calendar 2023, described as approximately 12 months after the last patient is randomized. The study is ongoing, and the company says disclosure restrictions prevent it from reporting interim arm data.
- Program prioritization: REM-001 remains paused; management estimated the pause would save approximately $3.0 million through calendar 2023. The company may further tailor or delay programs depending on available funding.
- Clinical and financing risks: The filing emphasizes the high failure risk of clinical trials, especially in glioblastoma, and risks that adequate capital may not be available on acceptable terms. Additional equity could dilute shareholders; debt or other financing could impose restrictive terms or require surrender of valuable rights.
- The filing reported no legal proceedings, no material changes to previously disclosed risk factors, and no subsequent events requiring disclosure in the financial statements. Management reported disclosure controls were effective and no material internal-control changes during the quarter.
Key facts for investors to verify
- Confirm the filing identity and reporting period: this source is Kintara’s March 31, 2023 Form 10-Q, not the requested Tuhura Biosciences 2022 Q3 filing.
- Check subsequent filings for liquidity, financing, going-concern disclosures, and whether any funding or partnership was secured.
- Verify the current status, enrollment, randomization timing, and results timetable for the VAL-083 GBM AGILE study.
- Confirm whether REM-001 remains paused and whether the stated cost savings were realized.
- Review potential dilution from preferred-stock conversions, warrants, options, and future equity financing.